Fibrin-mediated protection against infection-stimulated immunopathology

Journal of Experimental Medicine

Volumn 197, Issue 6, 2003, Pages 801-806

  Johnson, Lawrence L ^a   Berggren, Kiera N ^a   Szaba, Frank M ^a   Chen, Wangxue ^b   Smiley, Stephen T ^a  

^a TRUDEAU INSTITUTE   (United States)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

Blood coagulation; Cellular immunity; Hemorrhage; Interferon type II; Toxoplasma

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BLEEDING; BLOOD CLOTTING; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE EXACERBATION; FIBRIN DEPOSITION; FIBRIN METABOLISM; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION; INFECTION RISK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TOXOPLASMA GONDII;

ANIMALS; BLOOD COAGULATION; FIBRIN; IMMUNITY; INTERFERON TYPE II; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SURVIVAL RATE; TOXOPLASMA; TOXOPLASMOSIS;

EID: 0037451170     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20021493     Document Type: Article

References (30)

1. Nelson, D.S. 1965. The effects of anticoagulants and other drugs on cellular and cutaneous reactions to antigen in guinea pigs with delayed-type hypersensitivity. Immunology. 9:219-234.
2. Edwards, R.L., and F.R. Rickles. 1978. Delayed hypersensitivity in man: effects of systemic anticoagulation. Science. 200:541-543.
3. Colvin, R.B., M.W. Mosesson, and H.F. Dvorak. 1979. Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J. Clin. Invest. 63:1302-1306.
4. Holdsworth, S.R., N.M. Thomson, E.F. Glasgow, and R.C. Atkins. 1979. The effect of defibrination on macrophage participation in rabbit nephrotoxic nephritis: studies using glomerular culture and electronmicroscopy. Clin. Exp. Immunol. 37:38-43.
5. Neale, T.J., P.G. Tipping, S.D. Carson, and S.R. Holdsworth. 1988. Participation of cell-mediated immunity in deposition of fibrin in glomerulonephritis. Lancet. 2:421-424.
6. Kitching, A.R., S.R. Holdsworth, V.A. Ploplis, E.F. Plow, D. Collen, P. Carmeliet, and P.G. Tipping. 1997. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J. Exp. Med. 185:963-968.
7. Busso, N., V. Peclat, K. Van Ness, E. Kolodziesczyk, J. Degen, T. Bugge, and A. So. 1998. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J. Clin. Invest. 102:41-50.
8. Yang, Y.H., P. Carmeliet, and J.A. Hamilton. 2001. Tissue-type plasminogen activator deficiency exacerbates arthritis. J. Immunol. 167:1047-1052.
9. Paterson, P.Y. 1976. Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed. Proc. 35:2428-2434.
10. Inoue, A., C.S. Koh, K. Shimada, N. Yanagisawa, and K. Yoshimura. 1996. Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats. J. Neuroimmunol. 71:131-137.
11. Dvorak, H.F., M.C. Mihm, Jr., A.M. Dvorak, B.A. Barnes, E.J. Manseau, and S.J. Galli. 1979. Rejection of first-set skin allografts in man. The microvasculature is the critical target of the immune response. J. Exp. Med. 150:322-337.
12. Zhang, J., R. Munda, P. Glas-Greenwalt, M.A. Weiss, V.E. Pollak, and J.W. Alexander. 1983. Prolongation of survival of a heart xenograft by defibrination with ancrod. Transplantation. 35:620-622.
13. Labarrere, C.A., D.R. Nelson, and W.P. Faulk. 1998. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am. J. Med. 105:207-213.
14. Edwards, R.L., and F.R. Rickles. 1992. The role of leukocytes in the activation of blood coagulation. Semin. Hematol. 29:202-212.
15. Degen, J.L. 1999. Hemostatic factors and inflammatory disease. Thromb. Haemost. 82:858-864.
16. Esmon, C.T. 2001. Role of coagulation inhibitors in inflammation. Thromb. Haemost. 86:51-56.
17. Bernard, G.R., J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, A. Lopez-Rodriguez, J.S. Steingrub, G.E. Garber, J.D. Helterbrand, E.W. Ely, and C.J. Fisher, Jr. 2001. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344:699-709.
18. McCabe, R.E., and J.S. Remington. 1990. Toxoplasma gondii. 3rd ed. In Principles and Practices of Infectious Diseases. G.L. Mandell, R.G. Douglas, and J.E. Bennett, editors. Churchill Livingstone, Inc., New York. 2090-2103.
19. Denkers, E.Y., and R.T. Gazzinelli. 1998. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin. Microbiol. Rev. 11:569-588.
20. Suh, T.T., K. Holmback, N.J. Jensen, C.C. Daugherty, K. Small, D.I. Simon, S. Potter, and J.L. Degen. 1995. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 9:2020-2033.
21. Verdon, C.P., B.A. Burton, and R.L. Prior. 1995. Sample pretreatment with nitrate reductase and glucose-6-phosphate dehydrogenase quantitatively reduces nitrate while avoiding interference by NADP+ when the Griess reaction is used to assay for nitrite. Anal. Biochem. 224:502-508.
22. Overbergh, L., D. Valckx, M. Waer, and C. Mathieu. 1999. Quantification of murine cytokine mRNAs using real time quantitative reverse transcriptase PCR. Cytokine. 11:305-312.
23. Weiler-Guettler, H., P.D. Christie, D.L. Beeler, A.M. Healy, W.W. Hancock, H. Rayburn, J.M. Edelberg, and R.D. Rosenberg. 1998. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state. J. Clin. Invest. 101:1983-1991.
24. Smyth, S.S., E.D. Reis, H. Vaananen, W. Zhang, and B.S. Coller. 2001. Variable protection of beta 3-integrin-deficient mice from thrombosis initiated by different mechanisms. Blood. 98:1055-1062.
25. Suzuki, Y., M.A. Orellana, R.D. Schreiber, and J.S. Remington. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science. 240:516-518.
26. Moon, D.K., and C.L. Geczy. 1988. Recombinant IFN-gamma synergizes with lipopolysaccharide to induce macrophage membrane procoagulants. J. Immunol. 141:1536-1542.
27. Schwager, I., and T.W. Jungi. 1994. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood. 83:152-160.
28. Hamilton, J.A., G.A. Whitty, K. Last, A.K. Royston, P.H. Hart, and D.R. Burgess. 1992. Interleukin-4 suppresses plasminogen activator inhibitor-2 formation in stimulated human monocytes. Blood. 80:121-125.
29. Lou, X.J., N.W. Boonmark, F.T. Horrigan, J.L. Degen, and R.M. Lawn. 1998. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc. Natl. Acad. Sci. USA. 95:12591-12595.
30. Szaba, F.M., and S.T. Smiley. 2002. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 99:1053-1059.